Current Rheumatology Reports

, Volume 13, Issue 4, pp 308–316

Treatment of Mild, Moderate, and Severe Lupus Erythematosus: Focus on New Therapies

Article

Abstract

Despite large-scale efforts devoted to the conduct of clinical trials in systemic lupus erythematosus (SLE), no new therapy has been approved for treatment of this disease in more than 50 years. Increased understanding of the immunologic mechanisms underlying SLE has led to the development of a variety of biologic agents that target specific aspects of the adaptive and innate arms of the immune system, including B cells, T cells, dendritic cells, and various cytokines. One of these agents, belimumab, was the subject of two positive phase 3 trials in nonrenal lupus that have given us hope that a new therapy for SLE may be finally within our grasp. In addition to these newer therapies, recent studies of standard-of-care medications such as mycophenolate mofetil and hydroxychloroquine have better defined the efficacy and safety of these agents for the treatment of lupus nephritis and nonrenal lupus. This article provides a discussion of several novel biologic agents at different stages of development for the treatment of SLE, as well as an analysis of newer data on agents that have been used in the treatment of SLE for many years.

Keywords

Systemic lupus erythematosus Lupus nephritis Therapy Clinical trials Atacicept Rituximab Belimumab Epratuzumab Mycophenolate mofetil Interferon-alpha Abatacept Hydroxychloroquine 

References

Papers of particular interest, published recently, have been highlighted as: •• Of major importance

  1. 1.
    •• Mackay F, Figgett WA, Saulep D, et al. B-cell stage and context-dependent requirements for survival signals from BAFF to the B-cell receptor. Immunol Rev 2010, 237:205–25. This is a very detailed review of the role of BAFF in B-cell development, survival, and activation. PubMedCrossRefGoogle Scholar
  2. 2.
    Silverman GJ, Weisman S. Rituximab therapy and autoimmune disorders: prospects for anti-B cell therapy. Arthritis Rheum. 2003;48:1484–92.PubMedCrossRefGoogle Scholar
  3. 3.
    Merrill JT, Newelt CM, Wallace DJ, et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus. Arthritis Rheum. 2010;62:222–33.PubMedCrossRefGoogle Scholar
  4. 4.
    Furie R, Looney RJ, Rovin B, et al. Efficacy and safety of rituximab in subjects with active proliferative lupus nephritis (LN): results from the randomized, double-blind phase III LUNAR study. Arthritis Rheum. 2009;60:S429 [abstract 1149].Google Scholar
  5. 5.
    Terrier B, Amoura A, Ravaud P, et al. Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French Autoimmunity to Rituximab Registry. Arthritis Rheum. 2010;62:2458–66.PubMedCrossRefGoogle Scholar
  6. 6.
    Lu TY, Ng KP, Cambridge G, et al. A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London Hospital: the first 50 patients. Arthritis Care Res. 2009;61:482–7.CrossRefGoogle Scholar
  7. 7.
    Ramos-Casals M, Garcia-Hernandez FJ, de Ramon E, et al. Off-label use of rituximab in 196 patient with severe, refractory systemic autoimmune diseases. Clin Exp Rheumatol. 2010;28:468–76.PubMedGoogle Scholar
  8. 8.
    •• Murray E, Perry M. Off-label use of rituximab in systemic lupus erythematosus: a systematic review. Clin Rheumatol 2010, 29: 707–16. This is a systematic review of results of off-label use of rituximab for autoimmune disease. PubMedCrossRefGoogle Scholar
  9. 9.
    Calabrese LH, Molloy ES. Progressive multifocal leucoencephalopathy in the rheumatic diseases: assessing the risks of biological immunosuppressive therapies. Ann Rheum Dis. 2008;67 Suppl 3:iii64–5.PubMedCrossRefGoogle Scholar
  10. 10.
    Furie RA, Stohl W, Ginzler EM, et al. Biologic activity and safety of belimumab, a neutralizing anti-B lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus. Arthritis Res Ther. 2008;10:R109.PubMedCrossRefGoogle Scholar
  11. 11.
    Wallace DJ, Stohl W, Furie RA, et al. A phase II randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum. 2009;61:1168–78.PubMedCrossRefGoogle Scholar
  12. 12.
    Navarra S, Guzman R, Gallacher A, et al. Belimumab, a BLys-specific inhibitor, reduced disease activity, flares, and prednisone use in patients with active SLE: efficacy and safety results from the phase 3 BLISS-52 study. American College of Rheumatology 2009 Annual Scientific Meeting: Philadelphia, PA (17–21 October, 2009)Google Scholar
  13. 13.
    Furie RA, Zamani O, Wallace DJ, et al. Belimumab, a BLyS-specific inhibitor, reduced disease activity and severe flares in seropositive SLE patients: BLISS-76 study results through week 76. American College of Rheumatology 2010 Annual Scientific Meeting: Atlanta, GA (6–10 November, 2010)Google Scholar
  14. 14.
    Merrill JT, Wallace DJ, Furie RA, et al. Five-year experience with belimumab, a BLyS-specific inhibitor, in patients with systemic lupus erythematosus (SLE). American College of Rheumatology 2010 Annual Scientific Meeting: Atlanta, GA (6–10 November, 2010)Google Scholar
  15. 15.
    Dorner T, Kaufmann J, Wegener WA, et al. Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus. Arthritis Res Ther. 2006;8:R74–85.PubMedCrossRefGoogle Scholar
  16. 16.
    Wallace DJ, Kalunian KC, Petri MA, et al. Epratuzumab demonstrates clinically meaningful improvements in patients with moderate to severe systemic lupus erythematosus (SLE): results from EMBLEM, a phase IIb study. Arthritis Rheum. 2010;62:S605 [Abstract 1452].CrossRefGoogle Scholar
  17. 17.
    Dall’Era M, Chakravarty E, Wallace D, et al. Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus. Arthritis Rheum. 2007;56:4142–50.PubMedCrossRefGoogle Scholar
  18. 18.
    Merrill JT, Burgos-Vargas R, Westhovens R, et al. The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus. Arthritis Rheum. 2010;62:3077–87.PubMedCrossRefGoogle Scholar
  19. 19.
    •• Crow MK. Interferon-alpha: a therapeutic target in systemic lupus erythematosus. Rheum Dis Clin N Am 2010, 36: 173–86. This is an outstanding overview of the immunobiology of IFN-α and its role in autoimmune diseases. CrossRefGoogle Scholar
  20. 20.
    Niewold TN, Swedler WI. Systemic lupus erythematosus arising during interferon-alpha therapy for cryoglobulemic vasculitis associated with hepatitis C. Clin Rheumatol. 2005;24:178–81.PubMedCrossRefGoogle Scholar
  21. 21.
    Hooks JJ, Moutsopoulos HM, Geis SA, et al. Immune interferon in the circulation of patients with autoimmune disease. N Engl J Med. 1979;301:5–8.PubMedCrossRefGoogle Scholar
  22. 22.
    Crow MK, Kirou KA, Wohlgemuth J. Microarray analysis of interferon-regulated genes in SLE. Autoimmunity. 2003;36:481–90.PubMedCrossRefGoogle Scholar
  23. 23.
    Niewold TB, Clark DN, Salloum R, et al. Interferon alpha in systemic lupus erythematosus. J Biomed Biotechnol. 2010;2010:948364.PubMedCrossRefGoogle Scholar
  24. 24.
    Yao Y, Richman L, Higgs BW, et al. Neutralization of interferon-alpha/beta-inducible genes and downstream effect in a phase I trial of an anti-interferon-alpha monoclonal antibody in systemic lupus erythematosus. Arthritis Rheum. 2009;60:1785–96.PubMedCrossRefGoogle Scholar
  25. 25.
    McBride JM, Morimoto A, Drappa J. Genentech’s rontalizumab is well-tolerated by lupus patients in a phase I clinical trial. Lupus Foundation of America Website, accessed 11/28/2010. Available at http://www.lupus.org/webmodules/webarticlesnet/templates/new_empty.aspx?articleid=2844&zoneid=76
  26. 26.
    Chan TM, Li FK, Tang CS, et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative nephritis. Hong Kong-Guangzhou Nephrology Study Group. N Engl J Med. 2000;343:1156–62.PubMedCrossRefGoogle Scholar
  27. 27.
    Chan TM, Tse KC, Tang CS, et al. Hong Kong Nephrology Study Group. Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis. J Am Soc Nephrol. 2005;16:1076–84.PubMedCrossRefGoogle Scholar
  28. 28.
    Ginzler EM, Dooley MA, Aranow C, et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med. 2005;353:2219–28.PubMedCrossRefGoogle Scholar
  29. 29.
    Appel GB, Contreras G, Dooley MA, et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol. 2009;20:1103–12.PubMedCrossRefGoogle Scholar
  30. 30.
    Isenberg D, Appel GB, Contreras G, et al. Influence of race/ethnicity on response to lupus nephritis treatment: the ALMS study. Rheumatology. 2010;49:128–40.PubMedCrossRefGoogle Scholar
  31. 31.
    Radhakrishnan J, Moutzouris DA, Ginzler EM, et al. Mycophenolate mofetil and intravenous cyclophosphamide are similar as induction therapy for class V lupus nephritis. Kidney Int. 2010;77:152–60.PubMedCrossRefGoogle Scholar
  32. 32.
    Wofsy D, et al. Aspreva lupus management study maintenance results. Lupus 2010; 19 (Abstr. Suppl): 27 (Abstract CS12.5)Google Scholar
  33. 33.
    Houssiau FA, D’Cruz D, Sangle S, et al. Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN nephritis trial. Ann Rheum Dis 2010 (Epub ahead of print)Google Scholar
  34. 34.
    The Canadian Hydroxychloroquine Study Group. A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. N Engl J Med. 1991;324:150–4.CrossRefGoogle Scholar
  35. 35.
    The Canadian Hydroxychloroquine Study Group. A long-term study of hydroxychloroquine withdrawal on exacerbations in systemic lupus erythematosus. Lupus. 1998;7:80–5.CrossRefGoogle Scholar
  36. 36.
    Lafyatis R, York M, Marshak-Rothstein A. Antimalarial agents: closing the gate on Toll-like receptors? Arthritis Rheum. 2006;54:3068–70.PubMedCrossRefGoogle Scholar
  37. 37.
    Wallace DJ. Antimalarial therapies. In: Wallace D, Hahn B, editors. Dubois’ lupus erythematosus. 7th ed. Philadelphia: Lippincott Williams & Wilkins; 2007. p. 1152–74.Google Scholar
  38. 38.
    Barrat FJ, Meeker T, Gregorio J, et al. Nucleic acids of mammalian origin can act as endogenous ligands for Toll-like receptors and may promote systemic lupus erythematosus. J Exp Med. 2005;202:1131–9.PubMedCrossRefGoogle Scholar
  39. 39.
    •• Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P, et al. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann Rheum Dis 2010, 69: 20–8. This is a comprehensive, systematic review of the role of antimalarials in disease activity, damage, and toxicity related to SLE. PubMedCrossRefGoogle Scholar
  40. 40.
    Wolfe F, Marmor MF. Rates and predictors of hydroxychloroquine retinal toxicity in patients with rheumatoid arthritis and systemic lupus erythematosus. Arthritis Care Res. 2010;62:775–84.CrossRefGoogle Scholar
  41. 41.
    •• Izmirly PM, Kim MY, Llanos C, et al. Evaluation of the risk of anti-SSA/Ro-SSB/LA antibody-associated cardiac manifestations of neonatal lupus in fetuses of mothers with systemic lupus erythematosus exposed to hydroxychloroquine. Ann Rheum Dis 2010:69: 1827–30. This was an expertly performed study combining outcomes of three cohorts of infants born to mothers with SLE and anti-SSA/SSB antibodies. PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  1. 1.University of CaliforniaSan FranciscoUSA
  2. 2.Division of Immunology and RheumatologyStanford UniversityPalo AltoUSA

Personalised recommendations